Bank of New York Mellon Corp Has $2.84 Million Stake in Heron Therapeutics, Inc. (HRTX)

Bank of New York Mellon Corp lifted its position in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 7.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 204,857 shares of the biotechnology company’s stock after acquiring an additional 14,086 shares during the quarter. Bank of New York Mellon Corp’s holdings in Heron Therapeutics were worth $2,837,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in HRTX. Legal & General Group Plc lifted its holdings in shares of Heron Therapeutics by 13.9% in the 1st quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock worth $136,000 after acquiring an additional 1,098 shares during the last quarter. Tudor Investment Corp ET AL bought a new stake in shares of Heron Therapeutics in the 1st quarter worth about $253,000. Nationwide Fund Advisors lifted its holdings in shares of Heron Therapeutics by 11.3% in the 1st quarter. Nationwide Fund Advisors now owns 21,972 shares of the biotechnology company’s stock worth $330,000 after acquiring an additional 2,233 shares during the last quarter. Searle & CO. lifted its holdings in shares of Heron Therapeutics by 12.8% in the 2nd quarter. Searle & CO. now owns 26,500 shares of the biotechnology company’s stock worth $367,000 after acquiring an additional 3,000 shares during the last quarter. Finally, American International Group Inc. lifted its holdings in shares of Heron Therapeutics by 38.6% in the 1st quarter. American International Group Inc. now owns 25,332 shares of the biotechnology company’s stock worth $380,000 after acquiring an additional 7,059 shares during the last quarter.

ILLEGAL ACTIVITY NOTICE: “Bank of New York Mellon Corp Has $2.84 Million Stake in Heron Therapeutics, Inc. (HRTX)” was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://stocknewstimes.com/2017/10/11/bank-of-new-york-mellon-corp-has-2-84-million-stake-in-heron-therapeutics-inc-hrtx.html.

Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) opened at 16.35 on Wednesday. Heron Therapeutics, Inc. has a one year low of $12.21 and a one year high of $20.85. The company’s market cap is $885.16 million. The company’s 50-day moving average is $16.00 and its 200-day moving average is $15.17.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.90) by $0.10. The company had revenue of $8.51 million for the quarter, compared to analysts’ expectations of $4.53 million. On average, equities analysts predict that Heron Therapeutics, Inc. will post ($3.51) EPS for the current year.

Several equities research analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. BidaskClub lowered shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 18th. Noble Financial restated a “buy” rating on shares of Heron Therapeutics in a report on Thursday, August 10th. Cantor Fitzgerald set a $31.00 price objective on shares of Heron Therapeutics and gave the company a “buy” rating in a report on Friday, August 18th. Finally, Jefferies Group LLC reiterated a “buy” rating on shares of Heron Therapeutics in a report on Wednesday, August 16th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the company. Heron Therapeutics presently has an average rating of “Buy” and an average target price of $28.50.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply